HomeCompareGILD vs SLB

GILD vs SLB: Dividend Comparison 2026

GILD yields 2.34% · SLB yields 2.23%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GILD wins by $7.7K in total portfolio value
10 years
GILD
GILD
● Live price
2.34%
Share price
$136.34
Annual div
$3.19
5Y div CAGR
17.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.1K
Annual income
$1,614.90
Full GILD calculator →
SLB
SLB
● Live price
2.23%
Share price
$51.53
Annual div
$1.15
5Y div CAGR
-12.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$62.32
Full SLB calculator →

Portfolio growth — GILD vs SLB

📍 GILD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGILDSLB
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GILD + SLB cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GILD pays
SLB pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GILD
Annual income on $10K today (after 15% tax)
$198.88/yr
After 10yr DRIP, annual income (after tax)
$1,372.67/yr
SLB
Annual income on $10K today (after 15% tax)
$189.70/yr
After 10yr DRIP, annual income (after tax)
$52.97/yr
At 15% tax rate, GILD beats the other by $1,319.69/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GILD + SLB for your $10,000?

GILD: 50%SLB: 50%
100% SLB50/50100% GILD
Portfolio after 10yr
$25.3K
Annual income
$838.61/yr
Blended yield
3.32%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SLB right now

GILD
Analyst Ratings
37
Buy
20
Hold
1
Sell
Consensus: Buy
Price Target
$158.71
+16.4% upside vs current
Range: $105.00 — $180.00
Altman Z
4.1
Piotroski
8/9
SLB
Analyst Ratings
56
Buy
6
Hold
4
Sell
Consensus: Buy
Price Target
$52.95
+2.8% upside vs current
Range: $45.00 — $61.00
Altman Z
3.2
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GILD buys
0
SLB buys
0
No recent congressional trades found for GILD or SLB in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGILDSLB
Forward yield2.34%2.23%
Annual dividend / share$3.19$1.15
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR17.3%-12.7%
Portfolio after 10y$29.1K$21.4K
Annual income after 10y$1,614.90$62.32
Total dividends collected$7.6K$1.2K
Payment frequencyquarterlyquarterly
SectorHealthcareEnergy
Analyst consensusBuyBuy
Analyst price target$158.71$52.95

Year-by-year: GILD vs SLB ($10,000, DRIP)

YearGILD PortfolioGILD Income/yrSLB PortfolioSLB Income/yrGap
1← crossover$10,974$274.45$10,895$194.83+$79.00GILD
2$12,073$330.19$11,831$173.18+$242.00GILD
3$13,316$398.20$12,812$153.43+$504.00GILD
4$14,730$481.49$13,845$135.57+$885.00GILD
5$16,345$583.87$14,933$119.52+$1.4KGILD
6$18,199$710.26$16,084$105.19+$2.1KGILD
7$20,340$866.96$17,302$92.43+$3.0KGILD
8$22,826$1,062.22$18,594$81.13+$4.2KGILD
9$25,731$1,306.80$19,967$71.13+$5.8KGILD
10$29,147$1,614.90$21,427$62.32+$7.7KGILD

GILD vs SLB: Complete Analysis 2026

GILDHealthcare

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

Full GILD Calculator →

SLBEnergy

SLB N.V. engages in the provision of technology for the energy industry worldwide. The company operates through four divisions: Digital & Integration, Reservoir Performance, Well Construction, and Production Systems. The company provides field development and hydrocarbon production, carbon management, and integration of adjacent energy systems; reservoir interpretation and data processing services for exploration data; and well construction and production improvement services and products. It also offers subsurface geology and fluids evaluation information; stimulation services to restore or enhance well productivity through hydraulic fracturing, matrix stimulation, and water treatment; and intervention services to oil and gas operators. In addition, the company offers mud logging, directional drilling, measurement-while-drilling, and logging-while-drilling services, as well as engineering support services; supplies drilling fluid systems; designs, manufactures, and markets roller cone and fixed cutter drill bits; bottom-hole-assembly and borehole enlargement technologies; well planning, well drilling, engineering, supervision, logistics, procurement, and contracting of third parties, as well as drilling rig management solutions; and drilling equipment and services, as well as land drilling rigs and related services. Further, it provides artificial lift; supplies packers, safety valves, sand control technology, and various intelligent systems; midstream production systems; valves, chokes, actuators, and surface trees; and OneSubsea, an integrated solutions, products, systems, and services, including wellheads, subsea trees, manifolds and flowline connectors, control systems, connectors, and services. The company was formerly known as Schlumberger Limited and change its name to SLB N.V. in October 2025. SLB N.V. was founded in 1926 and is based in Houston, Texas.

Full SLB Calculator →
📬

Get this GILD vs SLB comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GILD vs SCHDGILD vs JEPIGILD vs OGILD vs KOGILD vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.